drugset / Trial / NCT05353361
A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the safety, tolerability and efficacy of SHR-A1811 in combination with pyrotinib or pertuzumab or adebrelimab or albumin-bound paclitaxel in patients with breast cancer.
Timeline
- Start
- 2022-05-23
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 0.6 g | Intravenous |
| Subject | Paclitaxel | Small molecule | 100 mg | Intravenous |
| Subject | Pertuzumab | Monoclonal antibody | 420 mg | Intravenous |
| Subject | Pyrotinib | Small molecule | 80 mg | Oral |
| Subject | Pyrotinib | Small molecule | 160 mg | Oral |
| Subject | Trastuzumab Rezetecan | Monoclonal antibody | 100 mg | Intravenous |